SCHEMBL802601

SCHEMBL802601

O=C(CCCC(=O)N1CCCC2CCCCC21)NC(c1ccccc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
KMT2A Q03164 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MEN1 O00255 2/20 0.47
HSD11B1 P28845 3/20 0.44
LMNA P02545 1/20 0.44
ACE P12821 5/20 0.43
ACE2 Q9BYF1 4/20 0.43
DUT P33316 1/20 0.42
KDM4E B2RXH2 1/20 0.42
PRCP P42785 1/20 0.42
GAA P10253 1/20 0.41
HSD17B1 P14061 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL772523 0.89 PRCP (0.50) ALDH1A1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL771118 0.89 PRCP (0.50) ALDH1A1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL770362 0.87 NPC1 (0.45) ALDH1A1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL10138695 0.86 ALDH1A1 (0.53) ALDH1A1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL771050 0.86 DPP4 (0.51) ALDH1A1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL771811 0.86 ALDH1A1 (0.53) ALDH1A1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL770883 0.86 DPP4 (0.46) NPC1RAB9ASMN1; SMN2HSD11B1ACE
SCHEMBL771117 0.85 NPC1 (0.47) KMT2ANPC1RAB9ASMN1; SMN2MEN1
SCHEMBL803113 0.85 NPC1 (0.43) KMT2AL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL772411 0.85 NPC1 (0.43) KMT2AL3MBTL1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 144/4885KMT2A 3868/4885L3MBTL1 4097/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ALDH1A1 142/4885KMT2A 3893/4885L3MBTL1 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.